furosemide has been researched along with piroxicam in 43 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (9.30) | 18.7374 |
1990's | 4 (9.30) | 18.2507 |
2000's | 12 (27.91) | 29.6817 |
2010's | 21 (48.84) | 24.3611 |
2020's | 2 (4.65) | 2.80 |
Authors | Studies |
---|---|
Ax, F; Bonham, NM; Hallberg, A; Karlén, A; Lennernäs, H; Winiwarter, S | 1 |
Cha, SH; Endou, H; Kanai, Y; Kojima, R; Kusuhara, H; Sekine, T; Sugiyama, Y; Tsuda, M; Utsunomiya-Tate, N | 1 |
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Faller, B; Wohnsland, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Avdeef, A; Tam, KY | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Gozalbes, R; Pineda-Lucena, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Buttar, D; Colclough, N; Gerhardt, S; MacFaul, PA; Maskos, K; Phillips, SD; Plowright, A; Steinbacher, S; Steuber, H; Tam, K; Whittamore, P | 1 |
Akamatsu, M | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Barton, P; Luker, T; Wenlock, MC | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K | 1 |
Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
Johnston, A; Ravic, M; Turner, P | 1 |
Lin, MS | 1 |
Ferber, HP; Hitoglou-Makedou, A; Lawson, M; Turner, P | 1 |
Kendall, MJ; Wilkins, MR; Woods, KL | 1 |
Baker, DE | 1 |
Hartmann, D; Kleinbloesem, CH; Lücker, PW; Vetter, G | 1 |
Amidon, GL; Hilgendorf, C; Langguth, P; Lipka, E; Regårdh, CG; Spahn-Langguth, H | 1 |
Escribano, E; Navarro, CR; Regué, JQ; Sala, XG; Salamanca, J | 1 |
Donoso, MD; Haskell, RJ; Schartman, RR | 1 |
2 review(s) available for furosemide and piroxicam
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Digoxin; Drug Interactions; Furosemide; Glyburide; Humans; Male; Piroxicam; Warfarin | 1990 |
2 trial(s) available for furosemide and piroxicam
Article | Year |
---|---|
Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diuresis; Double-Blind Method; Female; Furosemide; Humans; Indomethacin; Male; Middle Aged; Natriuresis; Piroxicam; Placebos; Potassium; Randomized Controlled Trials as Topic; Sodium; Urine | 1989 |
The effects of selective and non-selective inhibition of cyclo-oxygenase on frusemide-stimulated natriuresis.
Topics: Adult; Creatinine; Cyclooxygenase Inhibitors; Flurbiprofen; Furosemide; Humans; Indomethacin; Male; Natriuresis; Piroxicam; Stimulation, Chemical; Sulindac; Thiazines | 1986 |
39 other study(ies) available for furosemide and piroxicam
Article | Year |
---|---|
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
Topics: Humans; Intestinal Absorption; Jejunum; Models, Biological; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship | 1998 |
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
Topics: Amino Acid Sequence; Animals; Brain; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Estrone; Molecular Sequence Data; Ochratoxins; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Amino Acid; Xenopus laevis | 1999 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
Topics: Binding Sites; Crystallography, X-Ray; Drug Interactions; Humans; Pharmaceutical Preparations; Protein Binding; Protein Structure, Tertiary; Serum Albumin; Spectrometry, Fluorescence | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
Topics: Acids; Albumins; Drug Design; Humans; Hydrogen-Ion Concentration; Lipids; Molecular Structure; Pharmaceutical Preparations; Protein Binding | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Pharmaceutical Preparations; Protein Binding; Serum Albumin, Human; Spectrophotometry, Ultraviolet; Titrimetry | 2020 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |
Effects of piroxicam on natriuresis and kaliuresis in hypertensives and healthy volunteers.
Topics: Adult; Aged; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Natriuresis; Piroxicam; Potassium; Sodium; Time Factors | 1990 |
Piroxicam--furosemide drug interaction.
Topics: Aged; Aged, 80 and over; Drug Interactions; Female; Furosemide; Humans; Piroxicam; Time Factors | 1988 |
Study on the possible interaction between tenoxicam and furosemide.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Chromatography, High Pressure Liquid; Dinoprostone; Drug Interactions; Electrolytes; Female; Furosemide; Heart Rate; Humans; Kidney Function Tests; Male; Middle Aged; Natriuresis; Piroxicam; Prostaglandins E; Spectrophotometry, Ultraviolet | 1987 |
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Topics: Antipyrine; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Cell Membrane Permeability; Cellular Senescence; Coculture Techniques; Furosemide; HT29 Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Ketoprofen; Mannitol; Metoprolol; Microscopy, Electron; Piroxicam; Reproducibility of Results; Terbutaline | 2000 |
Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse.
Topics: Amoxicillin; Animals; Furosemide; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Mice; Models, Animal; Naproxen; Perfusion; Permeability; Pharmaceutical Preparations; Piroxicam; Ranitidine; Rats | 2012 |
Surfactant choice and the physical stability of nanosuspensions as a function of pH.
Topics: Dioctyl Sulfosuccinic Acid; Drug Compounding; Drug Stability; Furosemide; Hydrogen-Ion Concentration; Itraconazole; Ketoconazole; Nanoparticles; Piroxicam; Povidone; Surface-Active Agents; Suspensions | 2012 |